Alnylam Pharmaceuticals Inc (ALNY : NASDAQ)
Common Stock
$239.36
USD
+0.00 (%)
Last updated: 2026-09-17
Get ALNY alerts:
ALNY
Alnylam Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
+0.46%
1 Week
-7.22%
1 Month
+6.57%
YTD
-15.34%
Key Statistics
Market Cap
$32.03B
52W High
$495.55
52W Low
$197.81
P/E Ratio
41.48
50 Day MA
$250.96
200 Day MA
$314.27
Beta
0.30
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $242.60 | $245.63 | $239.50 | $245.51 | $245.51 | 954,012 |
| 9/16/2026 | $239.50 | $242.24 | $236.00 | $239.36 | $239.36 | 814,225 |
| 9/15/2026 | $246.99 | $247.43 | $237.44 | $238.27 | $238.27 | 2,175,150 |
| 9/14/2026 | $250.16 | $252.79 | $244.18 | $249.99 | $249.99 | 997,229 |
| 9/11/2026 | $248.05 | $254.08 | $246.01 | $248.68 | $248.68 | 1,177,421 |
| 9/10/2026 | $256.68 | $256.68 | $246.42 | $247.51 | $247.51 | 1,625,900 |
| 9/9/2026 | $257.07 | $261.98 | $253.28 | $258.00 | $258.00 | 1,426,300 |
| 9/8/2026 | $259.00 | $272.08 | $254.01 | $260.10 | $260.10 | 2,008,500 |
| 9/4/2026 | $258.58 | $266.85 | $258.02 | $266.11 | $266.11 | 1,430,900 |
| 9/3/2026 | $265.94 | $271.19 | $261.54 | $264.50 | $264.50 | 1,709,100 |
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 55.1% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
US$371.35
+55.1% Upside
Current Price
US$239.36
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.4%
Annualized
90-Day Vol
80.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$205.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$231.32 | US$196.42 – US$272.43 |
| 60 trading days | US$217.96 | US$172.94 – US$274.68 |
| 90 trading days | US$205.36 | US$154.70 – US$272.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Financials
- Revenue (TTM)
- $4.80B
- EBITDA
- $1.05B
- Profit Margin
- 16.13%
- ROE (TTM)
- 96.56%
- EPS (Diluted)
- 5.77
- Book Value
- 10.13
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ALNY.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
ALNY.US news timeline
1 article covering ALNY.US, most recent first
Latest